Peregrine Pharmaceuticals Inc. (PPHMP) 24.21 $PPHMP
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results and Recent Developments
Marketwire - Tue Sep 09, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the first quarter of fiscal year (FY) 2015 ended July 31, 2014 and provided an update on its advancing clinical pipeline led by its investigational immuno-oncology candidate bavituximab and reviewed other corporate developments.
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwire - Mon Sep 08, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"
.
Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015 Financial Results After Market Close on September 9, 2014
Marketwire - Tue Sep 02, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter fiscal year (FY) 2015 ended July 31, 2014 on September 9, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the first quarter ended July 31, 2014 of FY 2015 and will review recent progress of its clinical development programs.
Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression
Marketwire - Mon Aug 11, 7:02AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announces preclinical data further validating the potent immune-stimulatory mechanism of its phosphatidylserine (PS)-targeting immuno-oncology platform. Results show that the combination of a PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression while also demonstrating a significant increase in tumor-fighting T-cells into the tumor microenvironment compared to anti-PD-1 antibody treatment alone in an immune competent animal model of breast cancer. These data will be presented today at 12:00 PM EDT at ImVacS, the 9th Annual Immunotherapies and Vaccine Summit being held August 11-14, 2014 in Boston, Massachusetts. Bavituximab is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments
Marketwire - Mon Jul 14, 3:01PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the fourth quarter and the fiscal year (FY) 2014 ended April 30, 2014 and provided an update on its advancing clinical pipeline and other corporate developments.
Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014
Marketwire - Mon Jul 07, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the fourth quarter and fiscal year (FY) 2014 ended April 30, 2014 on July 14, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the fourth quarter ended April 30, 2014 of FY 2014 and will review recent progress of its clinical development programs.
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting
Marketwire - Tue Apr 01, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 105th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 5-9, 2014 in San Diego, California. Data to be presented include studies investigating the therapeutic potential of Peregrine's phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with irradiation as well as with approved and developmental cancer immunotherapies.
Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer
Marketwire - Fri Mar 14, 7:01AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of an update to the ongoing Investigator-Sponsored Trial (IST) of its immunotherapy bavituximab in combination with the chemotherapy sorafenib (Nexavar(R)) in patients with advanced hepatocellular carcinoma (HCC) or liver cancer. The oral presentation was given at the 67th Society of Surgical Oncology (SSO) Annual Cancer Symposium being held March 12-15, 2014 at the Phoenix Convention Center in Phoenix, Arizona.
Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies
Marketwire - Thu Mar 13, 7:02AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presented at two Keystone Symposia support the immune-stimulatory mechanism of action and therapeutic potential of the company's phosphatidylserine (PS)-targeting antibodies in both oncology and antiviral therapeutic areas. These data were detailed in presentations at the Keystone Immune Evolution in Cancer symposium in Whistler, British Columbia, Canada and the Keystone HIV Pathogenesis - Virus vs. Host symposium in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies
Marketwire - Tue Mar 11, 7:04AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presentations made validate the immune-stimulatory mechanism of its phosphatidylserine (PS) targeting platform while demonstrating that the combination of an anti-PS antibody and anti-CTLA-4 or anti-PD-1 antibody displayed superior tumor growth than either anti-CTLA-4 or anti-PD-1 antibody alone in animal tumor models. These data were outlined in two presentations at the Keystone Immune Evolution in Cancer meeting being held March 9-13, 2014 in Whistler, British Columbia, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments
Marketwire - Fri Mar 07, 7:01AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the third quarter of fiscal year (FY) 2014 ended January 31, 2014 and provided an update on its advancing clinical pipeline and other corporate developments.
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results and Recent Developments
Marketwire - Tue Sep 09, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the first quarter of fiscal year (FY) 2015 ended July 31, 2014 and provided an update on its advancing clinical pipeline led by its investigational immuno-oncology candidate bavituximab and reviewed other corporate developments.
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwire - Mon Sep 08, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"
. Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015 Financial Results After Market Close on September 9, 2014
Marketwire - Tue Sep 02, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter fiscal year (FY) 2015 ended July 31, 2014 on September 9, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the first quarter ended July 31, 2014 of FY 2015 and will review recent progress of its clinical development programs.
Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression
Marketwire - Mon Aug 11, 7:02AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announces preclinical data further validating the potent immune-stimulatory mechanism of its phosphatidylserine (PS)-targeting immuno-oncology platform. Results show that the combination of a PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression while also demonstrating a significant increase in tumor-fighting T-cells into the tumor microenvironment compared to anti-PD-1 antibody treatment alone in an immune competent animal model of breast cancer. These data will be presented today at 12:00 PM EDT at ImVacS, the 9th Annual Immunotherapies and Vaccine Summit being held August 11-14, 2014 in Boston, Massachusetts. Bavituximab is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments
Marketwire - Mon Jul 14, 3:01PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the fourth quarter and the fiscal year (FY) 2014 ended April 30, 2014 and provided an update on its advancing clinical pipeline and other corporate developments.
Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014
Marketwire - Mon Jul 07, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the fourth quarter and fiscal year (FY) 2014 ended April 30, 2014 on July 14, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the fourth quarter ended April 30, 2014 of FY 2014 and will review recent progress of its clinical development programs.
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting
Marketwire - Tue Apr 01, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 105th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 5-9, 2014 in San Diego, California. Data to be presented include studies investigating the therapeutic potential of Peregrine's phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with irradiation as well as with approved and developmental cancer immunotherapies.
Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer
Marketwire - Fri Mar 14, 7:01AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of an update to the ongoing Investigator-Sponsored Trial (IST) of its immunotherapy bavituximab in combination with the chemotherapy sorafenib (Nexavar(R)) in patients with advanced hepatocellular carcinoma (HCC) or liver cancer. The oral presentation was given at the 67th Society of Surgical Oncology (SSO) Annual Cancer Symposium being held March 12-15, 2014 at the Phoenix Convention Center in Phoenix, Arizona.
Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies
Marketwire - Thu Mar 13, 7:02AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presented at two Keystone Symposia support the immune-stimulatory mechanism of action and therapeutic potential of the company's phosphatidylserine (PS)-targeting antibodies in both oncology and antiviral therapeutic areas. These data were detailed in presentations at the Keystone Immune Evolution in Cancer symposium in Whistler, British Columbia, Canada and the Keystone HIV Pathogenesis - Virus vs. Host symposium in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies
Marketwire - Tue Mar 11, 7:04AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presentations made validate the immune-stimulatory mechanism of its phosphatidylserine (PS) targeting platform while demonstrating that the combination of an anti-PS antibody and anti-CTLA-4 or anti-PD-1 antibody displayed superior tumor growth than either anti-CTLA-4 or anti-PD-1 antibody alone in animal tumor models. These data were outlined in two presentations at the Keystone Immune Evolution in Cancer meeting being held March 9-13, 2014 in Whistler, British Columbia, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments
Marketwire - Fri Mar 07, 7:01AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the third quarter of fiscal year (FY) 2014 ended January 31, 2014 and provided an update on its advancing clinical pipeline and other corporate developments.
